Partnering
In-house pipeline
Our internal pipeline includes innovative therapeutic and diagnostic radiopharmaceutical assets against established targets, such as FAP, PSMA (prostate cancer), SSTR (neuroendocrine tumors), and αvβ6 integrin (pancreatic cancer). In addition, we in-license promising targeting molecules and develop them via the TetraKit Platform. TetraKit Technologies is interested in both in- and out-licensing opportunities around our in-house pipeline.
Platform Partnerships
We collaborate with partners and engage in co-development projects, offering best-in-class labelling of any class of biomolecule with astatine-211 and other radiohalogens. TetraKit Technologies is interested in collaborations with targeting molecule developers to jointly develop innovative and potent radiopharmaceuticals.
